应用增强心血管磁共振成像对缺血性心肌病的诊断价值研究

目的探讨应用增强心血管磁共振成像对缺血性心肌病的诊断价值研究。方法收集我院2016年8月至2018年8月收治的左心室扩张及收缩功能减低患者76例的影像学及临床资料,对76例患者进行CTA、CMR的扫描诊断比较心功能分级及结果。结果 CTA扫描76例患者,其中14例患者为扩张型心肌病,心功能1~2级(9/14)例,3~4级(5/14例);62例患者为缺血型心肌病,心功能1~2级(33/62)例,3~4级(29/62例)。CMR扫描诊断结果 :扩张型心肌病组患者存在延迟退化的几率为35.71%(5/14),明显低于缺血型心肌病组的87.09(54/62)(P<0.05);扩张型心肌病组非典型部位(肌壁间、片状、弥漫性)强化的比例为28.57(4/14),明显高于缺血型心肌病组,扩张型心肌病组心内膜下强化比例7.14%(1/14)明显低于缺血型心肌病组80.64%(50/62)(P<0.05)。结论缺血性心肌病采取增强心血管磁共振成像检测能够较好地显示心脏内部情况,对缺血性心肌病能够较为准确地评价。

Diagnostic Value of Enhanced Cardiovascular Magnetic Resonance Imaging for Ischemic Cardiomyopathy

Objective To explore the diagnostic value of enhanced ca rdiovascular magnetic resonance imaging for ischemic ca rdiomyopathy.Methods 76 patients with left ventricular dilatation and decreasing systolic function in our hospital from August 2016 to August 2018 were selected.The imaging and clinical data of 76 patients were collected.76 patients were diagnosed by CTA and CMR to compare cardiac functional grading and results.Results CTA scan of 76 patients showed that 14 patients were dilated ca rdiomyopathy with grade 1-2(9/14) and grade 3-4(5/14) of cardiac function,and 62 patients were ischemic ca rdiomyopathy with grade 1-2(33/62) and grade 3-4(29/62) of cardiac function.CMR scan showed that the probability of delay and degeneration was 35.71%(5/14) in patients with dilated cardiomyopathy,which was significantly lower than that in patients with ischemic cardiomyopathy(87.09 %(54/62))(P<0.05).The proportion of enhancement in atypical sites(intermuscular,flaky,diffuse) in the dilated cardiomyopathy group was 28.57(4/14),which was significantly higher than that in the ischemic cardiomyopathy group.The proportion of subendocardial enhancement in the dilated ca rdiomyopathy group was 7.14(1/14),which was significantly lower than that in the ischemic cardiomyopathy group(80.64%(50/62))(P<0.05).Conclusion Enhanced cardiovascular magnetic resonance imaging ca n better display the internal conditions of the heart for ischemic ca rdiomyopathy.and can accu rately evaluate ischemic ca rdiomyopathy.